BDNF

Brain-derived neurotrophic factor (BDNF) is a neurotrophin produced primarily in the brain, particularly by neurons and astrocytes, and plays a crucial role in neuronal survival, growth, and synaptic plasticity. Researchers primarily study BDNF to understand its involvement in cognitive processes, mood regulation, and its potential implications in various neurological disorders. Key findings indicate that exercise can significantly increase BDNF levels, which may mediate improvements in cognition and mood, while deficits in BDNF have been linked to conditions such as post-stroke depression and diabetes. Current research is exploring the physiological roles of BDNF in astrocytes and its therapeutic potential in neuroprotection and recovery following spinal cord injuries. Clinical evidence indicates that targeting BDNF pathways may offer promising strategies for addressing cognitive and mood disorders, highlighting its relevance in both basic and applied neuroscience.

Brain-Derived Neurotrophic Factor (BDNF), also known as Abrineurin, is an endogenous protein predominantly produced in the central nervous system, particularly in the brain. It belongs to the neurotrophin family, which is a group of growth factors known for their role in neuronal survival, development, and function. BDNF is synthesized by neurons and glial cells, including astrocytes, and is the most abundantly expressed neurotrophin in the brain. Researchers have extensively studied BDNF for its critical roles in neuroplasticity, cognitive processes, and mood regulation. BDNF is involved in various physiological functions, such as promoting neuronal survival, enhancing synaptic plasticity, and supporting learning and memory. It is also implicated in mood disorders, with evidence suggesting its involvement in conditions like depression and post-stroke depression. Exercise has been shown to increase BDNF levels, which may mediate improvements in cognition and mood. BDNF exerts its effects primarily through binding to the TrkB receptor, initiating a cascade of intracellular signaling pathways that promote neuronal growth and survival. These pathways include the PI3K/Akt, MAPK/ERK, and PLCγ pathways, which are crucial for synaptic plasticity and neuroprotection. The pharmacokinetic properties of BDNF are not well-documented, with limited data on its half-life and metabolism. Its clinical applications are still under investigation, with potential therapeutic roles in neurodegenerative diseases, mood disorders, and acute spinal cord injury. Regulatory approval for BDNF-based therapies is currently limited, and further research is needed to establish its clinical efficacy and safety.

BDNF acts primarily on the TrkB receptor, a receptor tyrosine kinase, leading to the activation of downstream signaling pathways such as PI3K/Akt, MAPK/ERK, and PLCγ. These pathways are involved in promoting neuronal survival, differentiation, and synaptic plasticity, contributing to cognitive and mood-related functions.

Brain-derived neurotrophic factor (BDNF) primarily exerts its effects through the activation of tropomyosin receptor kinase B (TrkB) receptors, initiating signaling cascades such as the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway. These pathways are crucial for promoting neuronal survival, differentiation, synaptic plasticity, and neurogenesis. While the role of BDNF in neuronal physiology is well characterized, its precise mechanisms in astrocytes and other cell types remain less understood.

Current evidence is limited regarding the specific physiological roles of BDNF in astrocytes, particularly in different brain regions and developmental stages, necessitating further research to elucidate these mechanisms. Additionally, the relationship between BDNF levels and cognitive or mood improvements in diabetic populations remains ambiguous, highlighting the need for larger randomized controlled trials that explore the effects of exercise on BDNF in individuals with diabetes. Furthermore, the mechanisms linking BDNF expression to post-stroke depression are not well understood, indicating a need for studies that investigate the temporal changes in BDNF levels following stroke and their correlation with depressive symptoms in diverse patient populations.